Field Application Scientist
About the job
- A four-year bachelor's degree in life sciences is required.
- At least 2 years of experience working in a technical commercial role supporting customers in pre-sales and post-sales situations is required.
- At least 2 years of practical experience with genetic and proteomic life science applications, such as next-generation sequencing, enzyme-linked immunosorbent assays, and lateral flow assays, is required.
- Proficiency in understanding Clinical Laboratory Improvement Amendments requirements as they relate to Laboratory Developed Tests is required.
- Computer literacy in Microsoft Word, Excel, and PowerPoint and the ability to use computer-based tools for reports, email, and general communication are required.
- Knowledge of life sciences, molecular biology, biotechnology, genetics, polymerase chain reaction, next-generation sequencing, bioinformatics, diagnostics, antibody-based assays, flow cytometry, imaging, lateral flow assays, and enzyme-linked immunosorbent assays is required.
- Excellent oral and written English communication is required, including the ability to communicate technical information to non-technical end users.
- The ability to operate independently and remotely, with at least one weekly meeting with a supervisor, is required.
- The ability to maintain a flexible travel schedule during the work week is required.
- Become an expert in applications supported by Fortis products, including experimental setup, troubleshooting, and accessory products and instrumentation.
- Conduct ongoing product and application presentations and training sessions for customers.
- Provide product-support consultations to customers regarding their applications.
- Participate in internal global field application calls to maintain product and application knowledge and proficiency.
- Troubleshoot issues with products currently on the market as needed.
- Communicate routinely with customers and the commercial organization, keeping all parties informed and up to date.
- Learn new product portfolios as they become available and train internal teams and customers on new offerings.
- Understand the technical details of open opportunities and discuss technical strategies with account managers and the internal science team to support successful opportunities.
- Draft and edit custom project proposals based on customer needs and Fortis Life Sciences capabilities.
- Conduct product demonstrations and technical presentations remotely and in person.
- Compare the technical benefits of Fortis products and identify the shortcomings of competing products.
- Help map bulk strategies for key accounts by recommending product types and volumes based on customer needs and workflows.
- Support customers in understanding the analytical validation required for their Laboratory Developed Tests.
- Respond to customer emails and phone calls in a timely manner.
- Escalate issues to the manager when necessary and design customer-facing plans to help customers troubleshoot and resolve issues promptly.
- Document solutions in Salesforce.com for the field team to access and reference.
- Host remote customer training sessions and presentations.
- Follow up with customers to ensure successful product adoption in their workflows.
- A bachelor's degree in biochemistry or molecular biology is preferred.
- A master's degree or PhD is preferred.
About the company
Fortis Life Sciences is a technology-driven financial services company that helps people make better financial decisions. Its flagship offering is a personalized financial planning tool that creates tailored plans for budgeting, saving, investing, and other financial needs, using data-driven insights to generate customized recommendations. Beyond planning, the company provides financial literacy education and a range of investment products, including mutual funds and ETFs, to broaden access to investment opportunities. The business differentiates itself by focusing on accessibility, transparency, and affordability, delivering an integrated suite that combines planning tools, educational resources, and investment options in one place. Fortis Life Sciences aims to empower individuals to manage their money more effectively and reach their financial goals by making financial services easier to understand and use.
Company Size
201-500
Company Stage
N/A
Total Funding
N/A
Headquarters
Boston, Massachusetts
Founded
2020
Get referred to Fortis Life Sciences
See people who can refer or advise you
Simplify's Take
What believers are saying
- May 12, 2026 Deliver Biosciences win validates AbNano for translational drug-delivery programs.
- May 28, 2026 NK-cell library targets CAR-NK and complex receptor discovery demand.
- 26 active locations and multiple manufacturing sites expand cross-sell into diagnostics and biologics.
What critics are saying
- Fortis still lacks disclosed funding and profitability, limiting acquisition and expansion flexibility.
- Heavy integration across six brands risks duplicate systems, slower launches, and margin dilution.
- Bigger reagent rivals can undercut AbNano and diagnostics; weak differentiation kills standalone demand.
What makes Fortis Life Sciences unique
- Fortis combines Abcore, Bethyl, IPOC, nanoComposix, and Vector Biolabs into one platform.
- May 28, 2026 AbNano Anti-NK library adds differentiated single-domain discovery capabilities.
- Three ISO 13485 GMP sites support diagnostics, antibodies, and viral-vector commercialization.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Disability Insurance
Life Insurance
401(k) Retirement Plan
Company News
Fortis Life Sciences awards 2026 AbNano(R) VHH Discovery grant to Deliver Biosciences for targeted drug delivery research. Grant program expands access to advanced single-domain antibody technologies to support the research and development of next-generation therapies. BOSTON and LONDON, May 12, 2026 (GLOBE NEWSWIRE) - Fortis Life Sciences and Deliver Biosciences today announced that Fortis named Deliver Biosciences as the inaugural recipient of the 2026 Fortis Grant Series. The Fortis Grant featured AbNano VHH Discovery services as an initiative to create greater opportunities for organizations using new technologies to develop high-potential therapeutic programs. "We look forward to applying AbNano(R) capabilities to advance our work in in vivo CAR-T and gene therapy." - George Tetley Many serious diseases remain difficult to treat because the biological targets that drive them are often difficult to access with conventional antibodies. Large antibody formats can struggle to penetrate dense tissues such as solid tumors, limiting their therapeutic potential. VHH antibodies offer a promising alternative. Their smaller size, low immunogenicity, and stability can help them move through tissue more effectively, bind with precision, and support new classes of treatments. For researchers and drug developers, this enables faster development timelines, reduced biological barriers, enhanced targeting precision, and new opportunities across cancer, autoimmune disease, gene therapy, and targeted drug delivery. The Fortis Grant Series gives academic institutions, nonprofit organizations, biotechnology and pharmaceutical companies access to antibody discovery services that are often too costly or specialized to build internally. "Many of the next breakthroughs in medicine will come from scientists solving difficult biological problems in areas such as cancer, immune disease and gene therapy," said Chris Woodward, senior director of sales and marketing, antibody solutions, at Fortis Life Sciences. "The grant series accelerates that work by providing the discovery expertise and antibody technologies needed to turn promising science into therapeutic candidates." Fortis reviewed applications from organizations worldwide and evaluated proposals based on scientific merit, innovation, feasibility, and potential downstream impact. The submission from George Tetley and Deliver Biosciences was selected as the winner. Deliver Biosciences is developing targeted drug delivery technologies designed to bring therapies directly to intended cells to support future therapeutic strategies for diseases including HIV, sickle cell disease, and neurodegenerative disorders. "Access to advanced discovery infrastructure can significantly influence what an emerging biotechnology company can pursue and how efficiently it can generate data, evaluate targets, and prioritize development paths," said George Tetley, Ph.D., co-founder and chief scientific officer of Deliver Biosciences. "We look forward to applying AbNano capabilities to advance our work in in vivo CAR-T and gene therapy, with the goal of bringing new therapies to patients." About Fortis Life Sciences Established in 2020, Fortis Life Sciences integrates specialized life science companies including Abcore, Arista Biologicals, Bethyl Laboratories, Empirical Bioscience, IPOC, nanoComposix and Vector Biolabs to help organizations move from discovery to commercialization with greater speed, continuity and control. By providing premium products, custom services and deep technical expertise, Fortis helps partners create, validate and manufacture proprietary solutions for complex scientific and operational requirements. Fortis serves organizations worldwide through a growing global footprint, including multiple cGMP-compliant manufacturing sites certified to ISO 13485. Learn more at fortislife.com About Deliver Biosciences Deliver Biosciences develops targeted nanoparticle delivery vectors designed to transport a broad range of therapeutic payloads safely and efficiently to specific cells in vivo, with a lead candidate progressing towards clinic for in vivo CAR-T therapy. Its platform is built to support cell reprogramming and next-generation modalities including gene editing, immunotherapy, and precision medicine. The company's focus spans cancer immunotherapy, with long-term applications in autoimmune, neurodegenerative, and cardiovascular diseases where significant unmet medical needs remain. Learn more at deliverbio.com Media Contact: Nick Bartosik Marketing Specialist Fortis Life Sciences [email protected]
Astraea Bio is proud to announce its collaboration with Fortis Life Sciences, a partnership that represents a significant step forward in its mission to advance the field of spatial biology and multi-omics research.
Fortis Life Sciences, a prominent market player, has introduced advanced LFA kits incorporating Au NPs, delivering up to 20 times greater sensitivity compared to traditional gold colloids.
The history of gold as a store of value goes back many centuries, laying the groundwork for its pivotal role in global economics. By the late 19th Century, several major global economies followed the Gold Standard, wherein many of the major currencies worldwide were fixed to gold at a set price per ounce.The World Gold Council carried out extensive studies on the use of gold over the years. In their findings, it has designated the period between 1660 and 1819 as the rise of the gold standard, marking a significant evolution in its usage. Subsequently, the period between 1820 and 1930 was considered the heyday of the gold standard, reflecting its peak influence. Following this era, the period spanning from 1931 to 1999 is what the World Gold Council terms “After the Gold Standard,” indicating a shift in the global economic landscape.Click here for the list of the ten best gold stocks to invest in.How the Days of the ‘Gold Standard' Faded AwayIn 1944, during the end of the WWII days, the United States hosted the Bretton Woods conference. This conference dealt with the need for a new international system replacing the Gold System and positioning the dollar at the center since the United States dominated the global economic and political scene
Fortis Life Sciences, LLC (“Fortis”) has acquired Toronto-based International Point of Care, Inc. (“IPOC”). IPOC develops and manufactures key compone